IL195201A - Composition for use in the treatment of a disease or condition caused or associated with hyperactive cholinergic nerve of the patient or exocrine glands in the patient and a method of reducing facial lines or wrinkles or removing asymmetry of the face - Google Patents

Composition for use in the treatment of a disease or condition caused or associated with hyperactive cholinergic nerve of the patient or exocrine glands in the patient and a method of reducing facial lines or wrinkles or removing asymmetry of the face

Info

Publication number
IL195201A
IL195201A IL195201A IL19520108A IL195201A IL 195201 A IL195201 A IL 195201A IL 195201 A IL195201 A IL 195201A IL 19520108 A IL19520108 A IL 19520108A IL 195201 A IL195201 A IL 195201A
Authority
IL
Israel
Prior art keywords
wrinkles
muscles
disease
skin
patient
Prior art date
Application number
IL195201A
Other languages
English (en)
Hebrew (he)
Other versions
IL195201A0 (en
Inventor
Matthias Marx
Susanne Grafe
Reiner Benecke
Dirk Dressler
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Matthias Marx
Susanne Grafe
Reiner Benecke
Dirk Dressler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL195201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa, Matthias Marx, Susanne Grafe, Reiner Benecke, Dirk Dressler filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IL195201A0 publication Critical patent/IL195201A0/en
Publication of IL195201A publication Critical patent/IL195201A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL195201A 2006-06-29 2008-11-10 Composition for use in the treatment of a disease or condition caused or associated with hyperactive cholinergic nerve of the patient or exocrine glands in the patient and a method of reducing facial lines or wrinkles or removing asymmetry of the face IL195201A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81775606P 2006-06-29 2006-06-29
PCT/EP2007/005754 WO2008000490A1 (en) 2006-06-29 2007-06-28 High frequency application of neurotoxic component of botulinum toxin

Publications (2)

Publication Number Publication Date
IL195201A0 IL195201A0 (en) 2009-08-03
IL195201A true IL195201A (en) 2015-11-30

Family

ID=38462381

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195201A IL195201A (en) 2006-06-29 2008-11-10 Composition for use in the treatment of a disease or condition caused or associated with hyperactive cholinergic nerve of the patient or exocrine glands in the patient and a method of reducing facial lines or wrinkles or removing asymmetry of the face

Country Status (17)

Country Link
US (3) US8557255B2 (enExample)
EP (2) EP2032157A1 (enExample)
JP (2) JP5897784B2 (enExample)
KR (3) KR20140142377A (enExample)
CN (1) CN101460190A (enExample)
AR (1) AR061669A1 (enExample)
AU (1) AU2007264008B2 (enExample)
BR (1) BRPI0713061A2 (enExample)
CA (1) CA2654214C (enExample)
CL (1) CL2007001911A1 (enExample)
IL (1) IL195201A (enExample)
MX (1) MX2009000253A (enExample)
RU (1) RU2453333C2 (enExample)
TW (1) TWI519310B (enExample)
UY (1) UY30450A1 (enExample)
WO (1) WO2008000490A1 (enExample)
ZA (1) ZA200808491B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CN101687018A (zh) * 2007-06-01 2010-03-31 德国麦氏大药厂 基于肉毒毒素的神经毒成分供应温度-稳定性固体肌肉松弛剂的方法
US7473429B1 (en) * 2007-07-27 2009-01-06 Renfroe J Ben Method for treatment of laminitis in animals
US8455459B2 (en) 2007-08-02 2013-06-04 Medicis Pharmaceutical Corporation Method of applying an injectable filler
US20090204101A1 (en) * 2007-08-20 2009-08-13 Wortzman Mitchell S Method of applying an injectable filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
ES2571792T3 (es) * 2008-03-31 2016-05-26 The Chemo-Sero-Therapeutic Res Inst Neurotoxina botulínica A2 para su uso en el tratamiento de la hiperactividad muscular en presencia de anticuerpos neutralizantes de tipo A1
JP5746624B2 (ja) 2008-08-29 2015-07-08 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 変化した持続性を有するクロストリジウム性神経毒
ES2426667T3 (es) * 2008-09-09 2013-10-24 Susanne Grafe Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano)
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2246065A1 (en) 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
JP5951490B2 (ja) * 2009-10-21 2016-07-13 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 非複合ボツリヌス神経毒素を精製するための方法およびシステム
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
EP2399601A1 (en) 2010-06-24 2011-12-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin therapy
EP2627318B1 (en) 2010-10-12 2017-08-16 Merz Pharma GmbH & Co. KGaA Formulation suitable for stabilizing proteins, which is free of mammalian excipients
RU2454170C1 (ru) * 2011-02-21 2012-06-27 Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации Способ лечения спастичности мышц у больных с позвоночно-спинномозговой травмой
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
CN105658662B (zh) * 2013-07-30 2022-05-27 莫茨制药有限及两合公司 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
EP3046470B1 (en) 2013-09-20 2022-02-23 MDDT Inc. Diagnosing and treating movement disorders
WO2015039206A1 (en) * 2013-09-20 2015-03-26 Mddt Inc. Diagnosing and treating movement disorders
EP3154572A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3154635A1 (en) * 2014-06-13 2017-04-19 Merz Pharma GmbH & Co. KGaA Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
ES2762951T3 (es) * 2015-04-24 2020-05-26 Consiglio Nazionale Ricerche Nuevo uso terapéutico de la neurotoxina botulínica serotipo A
WO2018146550A1 (en) * 2017-02-10 2018-08-16 De Maio Domingos Mauricio Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same
EP3927355A1 (en) * 2019-02-21 2021-12-29 Merz Pharma GmbH & Co. KGaA Novel uses of botulinum neurotoxin for the treatment of tremor
RU2721300C2 (ru) * 2019-10-17 2020-05-18 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ лечения нейрогенной дисфункции мочевого пузыря, проявляющейся функциональной инфравезикальной обструкцией у женщин
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US11925677B2 (en) 2021-07-12 2024-03-12 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
AU2020365148B2 (en) 2019-10-18 2022-10-27 Penland Foundation Botulinum toxin for use in treatment
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US11738071B2 (en) 2021-07-12 2023-08-29 Penland Foundation Treatment of acute and chronic kidney disease
WO2021137667A1 (ko) * 2019-12-30 2021-07-08 주식회사 에이티지씨 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888977A (en) * 1973-02-01 1975-06-10 Murray J Sanders Modified neurotoxin
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1602379A1 (en) * 1993-12-28 2005-12-07 Allergan, Inc. Botulinum toxin B for treating spastic muscle
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
CA2505933C (en) * 1997-07-15 2008-09-30 Richard A. Schmidt Use of botulinum toxin for treating urinary incontinence
DK1023410T3 (da) * 1998-07-07 2006-08-14 Sun Chemical Corp Kationisk hærdelige litografiske trykfarver med lave indhold af flygtige organiske forbindelser
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
JP3694238B2 (ja) 1998-09-11 2005-09-14 バークシャー ラボラトリーズ，インコーポレイティド 音響エネルギーを使用する誘導電流の生成および感知
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6348434B1 (en) * 1999-07-01 2002-02-19 Basf Aktiengesellschaft Herbicidal emulsifiable concentrate
US20030180289A1 (en) * 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
JP2003512603A (ja) 1999-10-05 2003-04-02 テクノロジィ ファイナンス コーポレイション（プロプライエタリー） リミテッド 回転軸におけるトルクによるねじれの測定
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
AU770851B2 (en) 1999-10-14 2004-03-04 Mine Safety Appliances Company Lanyard with integral fall arrest energy absorber
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7226605B2 (en) * 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US20050106183A1 (en) * 2002-01-31 2005-05-19 Lamb Gregory B. Method of treating pain
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
AU2003227362A1 (en) 2002-08-06 2004-03-03 Genox Research, Inc. Method of examining atopic dermatitis
US7824693B2 (en) * 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US7288259B2 (en) * 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US20040115222A1 (en) * 2002-09-06 2004-06-17 Michael Kane Method for reduction of wrinkles
EP1398907B1 (de) * 2002-09-10 2010-12-08 Siemens Aktiengesellschaft Verfahren zur Kontrolle von Übertragungsressourcen eines paketorientierten Kommunikationsnetzes bei Topologieänderungen
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20050042775A1 (en) * 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US20050144029A1 (en) * 2003-12-31 2005-06-30 Rakowski Richard R. Systems and methods for aesthetic improvement
ATE451117T1 (de) * 2004-01-05 2009-12-15 Botulinum Toxin Res Ass Inc Verfahren zur verwendung von botulinustoxin zur behandlung von hypervolämischer lippendeformität (lippen-ektropion)
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
EP1799254A1 (en) * 2004-09-27 2007-06-27 Merz Pharma GmbH & Co.KGaA Clostridial neurotoxins for use in tissue healing
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
CA2595115C (en) * 2004-12-01 2014-01-21 Health Protection Agency Fusion proteins for treating, preventing or ameliorating pain
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
WO2006094539A1 (en) * 2005-03-03 2006-09-14 Université Catholique de Louvain Methods and compositions for the treatment of cancer
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
WO2008039245A2 (en) * 2006-04-27 2008-04-03 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CN101687018A (zh) * 2007-06-01 2010-03-31 德国麦氏大药厂 基于肉毒毒素的神经毒成分供应温度-稳定性固体肌肉松弛剂的方法
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
US9038912B2 (en) * 2007-12-18 2015-05-26 Microsoft Technology Licensing, Llc Trade card services
JP5746624B2 (ja) * 2008-08-29 2015-07-08 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 変化した持続性を有するクロストリジウム性神経毒
EP2398824B1 (en) * 2009-02-19 2018-12-26 Merz Pharma GmbH & Co. KGaA Means and methods for manufacturing highly pure neurotoxin
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
HUE029697T2 (en) * 2010-01-22 2017-03-28 Merz Pharma Gmbh & Co Kgaa To quantify the activity of clostridial neurotoxin in an in vitro assay
JP2015504304A (ja) * 2011-11-09 2015-02-12 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー ポリ−グリシンを伴う修飾神経毒及びその使用
CN105658662B (zh) * 2013-07-30 2022-05-27 莫茨制药有限及两合公司 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用

Also Published As

Publication number Publication date
JP2014015476A (ja) 2014-01-30
CA2654214C (en) 2023-07-04
US20080003241A1 (en) 2008-01-03
CA2654214A1 (en) 2008-01-03
CL2007001911A1 (es) 2008-03-14
UY30450A1 (es) 2009-04-30
CN101460190A (zh) 2009-06-17
WO2008000490A1 (en) 2008-01-03
RU2453333C2 (ru) 2012-06-20
US9095523B2 (en) 2015-08-04
KR20090027732A (ko) 2009-03-17
IL195201A0 (en) 2009-08-03
TWI519310B (zh) 2016-02-01
MX2009000253A (es) 2009-01-22
ZA200808491B (en) 2009-11-25
JP5897784B2 (ja) 2016-03-30
RU2009102848A (ru) 2010-08-10
US20140010803A1 (en) 2014-01-09
US20150290303A1 (en) 2015-10-15
US8557255B2 (en) 2013-10-15
KR20150126979A (ko) 2015-11-13
US9572871B2 (en) 2017-02-21
JP2009541396A (ja) 2009-11-26
BRPI0713061A2 (pt) 2012-04-10
TW200819140A (en) 2008-05-01
KR20140142377A (ko) 2014-12-11
AR061669A1 (es) 2008-09-10
EP2484373A1 (en) 2012-08-08
EP2032157A1 (en) 2009-03-11
AU2007264008A1 (en) 2008-01-03
AU2007264008B2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
IL195201A (en) Composition for use in the treatment of a disease or condition caused or associated with hyperactive cholinergic nerve of the patient or exocrine glands in the patient and a method of reducing facial lines or wrinkles or removing asymmetry of the face
IL264796B (en) History of 6,23-metabolized bile acid, pharmaceutical preparations acceptable in a pharmacy and compounds for use in a method for treating or preventing a disease
ZA201007460B (en) Use of epothelone in treating tau-associated disease including alzheimer's disease
EP1998788A4 (en) COMPOSITIONS AND METHODS FOR THE TOPIC TREATMENT OF DERMATOLOGICAL DISORDERS RESPONSIBLE FOR TAR
IL207559A0 (en) Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
IL209546A0 (en) Method and device for characterizing the effect of a skin treatment agent on skin
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
EP2091454A4 (en) APPARATUS AND METHOD FOR SKIN TREATMENT
EP2244786A4 (en) SKIN TREATMENT DEVICE FOR PERSONAL USE AND USE METHOD THEREFOR
EP2323597A4 (en) HEALTHY SKIN TREATMENT APPARATUS FOR PERSONAL USE AND METHOD OF USE
IL230911A0 (en) A system for the treatment of heart tissue and its use
EP2334249A4 (en) METHOD AND DEVICE FOR SKIN CARE
GB0912941D0 (en) Methods and composition for reduction of side effects of therapeutic treatments
IL273964B (en) A cosmetic method for the treatment of skin tissue
PL2083837T3 (pl) Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym
WO2008070859A3 (en) Treatment of skin conditions by dickkopf1 (dkk1)
EP2051732A4 (en) DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR
EP2274411A4 (en) XANTHOHUMOL COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES OR CONDITIONS
GB0426255D0 (en) Improvements in and relating to products for skin treatment
EG26132A (en) Device for the treatment of skin
WO2008028097A3 (en) Method for skin care
GB0805357D0 (en) Method of treating learning impairment in down's syndrome subjects
GB0718918D0 (en) Compositions and methods for treating skin conditions
EP1922063A4 (en) METHOD FOR TREATING PAIN IN PATIENTS
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed